Healthcare
Medios AG(MEDOF)
Live Price
Offline$50.00
+0.00% today
1Y Change
+0.00%
Window
Jun 26, 2025 โ Jun 18, 2026
- Market Cap
- $340.00M
- Revenue Growth
- +5.5%
- EPS Growth
- -35.4%
- Dividend Yield
- 0.0%
Coverage: 252 bars ยท Jun 26, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Medios AG (MEDOF) is a Healthcare stock with a market cap of $340.00M and listed on OTC. The stock last traded around $50.00 and up 0.0% across the available one-year price window (Jun 26, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +5.5%, EPS growth of -35.4%, a dividend yield of 0.0%. What stands out right now is revenue +5.5%, EPS -35.4%, free cash flow +344.8% with operating margin 2.2% and ROIC 3.4%. Valuation is more restrained than many high-expectation growth names at P/E 21.9 and price/sales 0.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines MEDOF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+5.5% vs +7.6% peer median
Operating Margin
Below sector median
+2.2% vs +19.4% peer median
P/E
Below sector median
21.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +5.5% and EPS is at -35.4%, with operating margin around 2.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Mar 26, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Nov 11, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Edge
MEDOF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MEDOF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MEDOF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MEDOF and SPY.
Company Overview
Medios AG
Other OTC
Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies; and patient-specific therapies for dispensing individually dosed tablets. The company was founded in 2016 and is based in Berlin, Germany.
- Leadership
- Thomas Meier
- IPO Date
- Nov 10, 2021
- Employees
- 472
- Street Address
- Heidestrasse 9
- Mailing
- Berlin, 10557
- Region
- Berlin, DE
- Reporting Currency
- USD
- Investor Line
- 49 30 232 5668 00
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 21.9
- EV/EBITDA
- 5.3
- Price/Sales
- 0.2
- Price/Book
- 0.7
Growth
- Revenue
- +5.5%
- EPS
- -35.4%
- Free Cash Flow
- +344.8%
Profitability
- Gross Margin
- 8.3%
- Operating Margin
- 2.2%
- Net Margin
- 0.7%
- ROE
- 3.0%
- ROIC
- 3.4%
Balance Sheet
- Debt/Equity
- 0.37
- Current Ratio
- 1.90
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.